Author

U. Manne

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Organism:mouse· 1

Frequent Co-Authors

D. S. Chandrashekar· 2 shared G. Naik· 2 shared G. Sonpavde· 2 shared J. E. Ferguson· 2 shared M.-L. Eich· 2 shared S. Agarwal· 2 shared S. Varambally· 2 shared A. B. Keeton· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. S. Chandrashekar

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer

J. Foote, T. E. Mattox, A. B. Keeton, X. Chen, F. T. Smith, K. L. Berry, T. W. Holmes, J. Wang, C.-H. Wang, A. B. Ward, A. K. Mitra, V. R. Alcantara, C. Hardy, K. G. Fleten, K. Flatmark, , G. A. Piazza

This paper introduces ADT-007, a novel pan-RAS inhibitor that effectively blocks tumor growth in mouse models of GI cancer by targeting RAS activation and inducing apoptosis.

bioRxiv · May 17, 2023 · PreprintCancer Biology

ARID1A-mutant and deficient bladder cancer is sensitive to EZH2 pharmacologic inhibition

J. E. Ferguson, H. Rehman, D. S. Chandrashekar, B. Chakravarthi, S. Nepal, M.-L. Eich, A. Robinson, S. Agarwal, S. A. H. Balasubramanya, G. Naik, U. Manne, G. Netto, C.-x. Pan, G. Sonpavde, S. Varambally

This study shows that ARID1A-deficient bladder cancer cells are sensitive to EZH2 inhibition, suggesting a therapeutic strategy for patients with ARID1A mutations.

bioRxiv · Jan 12, 2021 · PreprintCancer Biology

Therapeutically actionable PAK4 is amplified, overexpressed and involved in bladder cancer progression

D. S. Chandrashekar, B. V. S. K. Chakravarthi, A. D. Robinson, J. C. Anderson, S. Agarwal, S. A. Hodigere Balasubramanya, M.-L. Eich, A. K. Bajpai, S. Davuluri, M. S. Guru, A. S. Guru, G. Naik, D. L. Della Manna, K. K. Acharya, S. Carskadon, , S. Varambally

This study identifies PAK4 amplification and overexpression in bladder cancer and shows PAK4 inhibition reduces tumor growth, with potential for combination therapy.

bioRxiv · Aug 20, 2019Cancer Biology